Tesaro

TESARO, Inc.
Public
Traded as NASDAQ: TSRO
Russell 1000 Component
Industry Pharmaceuticals
Founded 2010 in Waltham, Massachusetts
Products Varubi
Number of employees
 286 (2016)
Website tesarobio.com

Tesaro is a public pharmaceutical company based in Waltham, Massachusetts. They focus on drug development for cancer.

History

Tesaro was founded in 2010.[1] The company's first commercial product, Varubi, was approved by the FDA in October 2015.[2] As of 2016, the company had 286 full-time employees, 59 of whom had a PhD or MD.[3] The company's product Niraparib was granted priority review and was given a target action date of June 2017 by the FDA.[4] In March 2017, Tesaro won approval for its drug Zejula to treat ovarian cancer.[5] On May 31, 2017, it was reported that Tesaro Inc. was exploring a sale.[5]

Products under development

  • Rolapitant – intravenous form in phase III clinical trials for use in chemotherapy-induced nausea and vomiting
  • Niraparib – PARP inhibitor in clinical trials for breast and ovarian cancer.[6]
  • TSR-042
  • TSR-022

References

  1. ↑ "Tesaro". FierceBiotech. Retrieved 2017-02-25.
  2. ↑ "TESARO - Quarterly Report". Ir.tesarobio.com. Retrieved 2017-02-25.
  3. ↑ "TESARO - Annual Report". Ir.tesarobio.com. Retrieved 2017-02-25.
  4. ↑ ESARO (TSRO) Announces Priority FDA Review for Niraparib NDA, Street Insider, December 20, 2016, Archived from the original on December 21, 2016, retrieved June 8, 2017
  5. 1 2 D. Rockoff, Jonathan; Cimilluca, Dana (May 31, 2017). "Tesaro Explores Sale". Wall Street Journal. New York City, New York. Retrieved June 1, 2017.
  6. ↑ "2016 Press Release: Niraparib Significantly Improves Outcome of Ovarian Cancer Patients in Landmark Trial". ESMO. Retrieved 2017-02-25.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.